ANNAPOLIS, Md. and PRINCETON, N.J., Jan. 8 /PRNewswire-FirstCall/ --
PharmAthene, Inc., (Amex: PIP) a biodefense company developing medical
countermeasures against biological and chemical threats, and Medarex, Inc.
(Nasdaq: MEDX), a leading monoclonal antibody company, today announced that
the FY 2008 U.S. Congressional appropriation for the Department of Defense
(DoD) includes up to $1.6 million payable to PharmAthene on a cost
reimbursement basis to support ongoing development of Valortim(TM), a fully
human monoclonal antibody generated by Medarex's UltiMAb(R) technology that
is being co-developed by the two companies for the prevention and treatment
of anthrax infection.
David P. Wright, President and Chief Executive Officer of PharmAthene
commented, "We're very pleased by the U.S. Government's ongoing support of
Valortim and commitment to advancing this important product for
consideration as part of our Nation's arsenal to protect against the
devastating consequences of an anthrax attack. Total government funding
pledged in support of Valortim over the last four fiscal years is up to $23
million, excluding this FY 08 appropriation."
Mr. Wright continued, "Valortim has demonstrated potent activity in
neutralizing the anthrax toxin in preclinical studies as well as favorable
safety data collected from our Phase I clinical study. We believe that
Valortim may have important competitive advantages which, if demonstrated,
would make it a strong choice for procurement consideration in the
Strategic National Stockpile."
"This funding will contribute to the continued development of this
potentially important biodefense product. Together with PharmAthene we
continue to advance the development of Valortim and believe that data
collected to date -- from preclinical and clinical research -- show that
Valortim could become an important part of the government's biodefense
program to prevent and treat anthrax infection," said Israel Lowy, M.D.,
Ph.D., Senior Director of Infectious Disease for Medarex.
About Valortim
Valortim (MDX-1303) is a fully human antibody designed to protect
against anthrax infection, including inhalation anthrax, the most lethal
form of illness in humans caused by the Bacillus anthracis bacterium. The
investigational antibody is designed to target a protein component known as
the anthrax protective antigen (PA) of the lethal toxin complex produced by
the bacterium. The anthrax protective antigen is believed to initiate the
onset of the illness by attaching to cells in the infected person, and then
is believed to facilitate the entry of additional destructive toxins into
the cells. Valortim is designed to target anthrax protective antigen and
protect the cells from damage by the anthrax toxins.
Valortim has been administered intravenously and intramuscularly to
healthy human volunteers in a completed phase I study, was well tolerated
at doses as high as 20 mg/kg (IV), and was not immunogenic. These study
results were presented at the 2006 Annual Meeting of the Infectious
Diseases Society of America. Pharmacokinetic analysis suggested that doses
as low as 1 mg/kg resulted in circulating levels of antibody after a month,
with a similar potency for neutralizing anthrax toxin in vitro as was seen
with serum obtained from subjects who had been vaccinated with anthrax
vaccine.
Preclinical studies suggest that Valortim has the potential to provide
significant protection against anthrax infection when administered
prophylactically (prior to the emergence of symptoms of anthrax infection)
and also may increase survival when administered therapeutically (once
symptoms become evident).
About Anthrax
According to the Centers for Disease Control and Prevention, anthrax is
an acute infectious disease caused by the spore-forming bacterium Bacillus
anthracis. Anthrax most commonly occurs in hoofed mammals and can also
infect humans. Symptoms of disease vary depending on how the disease is
contracted, but usually occur within seven days after exposure. The serious
forms of human anthrax are inhalation anthrax, cutaneous anthrax, and
intestinal anthrax. Initial symptoms of inhalation anthrax infection may
resemble a common cold. After several days, the symptoms may progress to
severe breathing problems and shock. Inhalation anthrax is often fatal,
even if treated by antibiotics. Currently, antibiotics are the only drugs
available for therapeutic or prophylactic use, and post-exposure
prophylaxis is the only FDA-approved indication for such products. However,
antibiotic therapy, while useful, is believed to be associated with a
number of limitations, including: (1) lack of activity against the toxins
produced by the B. anthracis bacteria (2) need for long-term dosing to
achieve full protection, complicated by side effects and non-compliance (3)
lack of efficacy when administered late in the anthrax disease cycle, and
(4) lack of effectiveness against multi-drug resistant or genetically
engineered strains of anthrax.
About PharmAthene, Inc.
PharmAthene (Amex: PIP) was formed to meet the critical needs of the
United States and its allies by developing and commercializing medical
countermeasures against biological and chemical weapons. PharmAthene's lead
programs include Valortim(TM) for the prevention and treatment of anthrax
infection and Protexia(R) for the prevention and treatment of morbidity and
mortality associated with exposure to chemical nerve agents. For more
information on PharmAthene, please visit http://www.PharmAthene.com.
About Medarex, Inc.
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 30 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase III clinical trials. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Statement on Cautionary Factors
For PharmAthene: Except for the historical information presented
herein, matters discussed may constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995 that
are subject to certain risks and uncertainties that could cause actual
results to differ materially from any future results, performance or
achievements expressed or implied by such statements. Statements that are
not historical facts, including statements preceded by, followed by, or
that include the words "potential"; "believe"; "anticipate"; "intend";
"plan"; "expect"; "estimate"; "could"; "may"; "should"; "could"; or similar
statements are forward-looking statements. PharmAthene disclaims, however,
any intent or obligation to update these forward-looking statements. Risks
and uncertainties include risks associated with the reliability of the
results of the studies relating to human safety and possible adverse
effects resulting from the administration of Valortim in humans, timely and
successful development of an efficient and scalable manufacturing process,
unexpected funding delays by NIAID/BARDA, unforeseen safety issues
resulting from the handling of Bacillus anthracis, as well as risks
detailed from time to time in PharmAthene's public disclosure filings with
the U.S. Securities and Exchange Commission (the "SEC"). There can be no
assurance that such development efforts will succeed or that other
developed products will receive required regulatory clearance or that, even
if such regulatory clearance were received, such products would ultimately
achieve commercial success. Copies of PharmAthene's public disclosure
filings are available from its investor relations department.
For Medarex: Except for the historical information presented herein,
matters discussed herein may constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995 that
are subject to certain risks and uncertainties that could cause actual
results to differ materially from any future results, performance or
achievements expressed or implied by such statements. Statements that are
not historical facts, including statements preceded by, followed by, or
that include the words "potential"; "believe"; "suggest"; "may"; "appear";
or similar statements are forward-looking statements. Medarex disclaims,
however, any intent or obligation to update these forward-looking
statements, except as required by law. Risks and uncertainties include
risks associated with the reliability of the results of the initial work
conducted on Valortim relating to animal efficacy, human safety and
likelihood of successful development of an efficient and scalable
manufacturing process, unexpected funding delays by NIAID/BARDA, unforeseen
safety issues resulting from the handling of Bacillus anthracis, unforeseen
safety issues resulting from the administration of Valortim(TM) (MDX-1303)
in human subjects, uncertainties related to product manufacturing as well
as risks detailed from time to time in Medarex's public disclosure filings
with the U.S. Securities and Exchange Commission (SEC), including its
Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and
its quarterly reports on Form 10-Q. There can be no assurance that such
development efforts will succeed or that other developed products will
receive required regulatory clearance or that, even if such regulatory
clearance were received, such products would ultimately achieve commercial
success. Copies of Medarex's public disclosure filings are available from
its investor relations department.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved. Valortim(TM) is a trademark of
PharmAthene, Inc. All rights are reserved.
SOURCE Medarex, Inc. and PharmAthene, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.PharmAthene.com
http://www.prnewswire.com/comp/108265.html/
CONTACT:
Stacey Jurchison, Director, Corporate
Communications of PharmAthene, Inc., +1-410-269-2610,
jurchisons@pharmathene.com; Laura S. Choi, Investor Relations,
+1-609-430-2880, x2216, or Jean Mantuano, Corporate
Communications (media), +1-609-430-2880, x2221, both of Medarex,
Inc.
|
